Subtype
Malignant Neoplasm of Unknown Primary
CI-CAN-00001150CUPExplore in graph →
4,163 active trials54 approved drugs532 evidence items
- NCIt
- C8566
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001150CUPExplore in graph →
Clinical trials
14,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,895)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02470897 | Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer | completed | N/A | 115 | University of Wisconsin, MadisonOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT03037437 | Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer | completed | Phase 2 | 64 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Sep 4, 2025 |
| clinicaltrials |
| NCT04879849 | A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers | completed | Phase 1 | 34 | TakedaINDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT05017662 | A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072 | completed | N/A | 20 | Ariceum Therapeutics GmbHINDUSTRY | 6 | Sep 4, 2025 | clinicaltrials |
| NCT02820857 | Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer(BEVANEC) | completed | Phase 2 | 153 | Hospices Civils de LyonOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT05263245 | The Pharmacological Effects of Using Cabozantinib With a Light Breakfast(Skippy 1) | completed | Phase 2 | 12 | dr. Tom van der HulleOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT03552965 | Margin-Based Vs. Robust Photon Radiotherapy Planning in IMRT of HN-SQCC | completed | N/A | 23 | University of ArkansasOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05323656 | A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) | completed | Phase 2 | 55 | Calliditas Therapeutics Suisse SAINDUSTRY | 7 | Sep 2, 2025 | clinicaltrials |
| NCT06439745 | More Than 50% of Unifocal cN0 T1b/Small T2 Papillary Thyroid Carcinoma May Require Completion Thyroidectomy if Nodal Status is Evaluated(cN0PTC) | completed | — | 314 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Sep 2, 2025 | clinicaltrials |
| NCT02973997 | Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) | completed | Phase 2 | 57 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT03300557 | Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Aug 29, 2025 | clinicaltrials |
| NCT03724994 | Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer(CHAMP) | completed | — | 201 | Lund UniversityOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT05509699 | Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 21 | Hutchison Medipharma LimitedINDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT06272513 | Influencing Factors for Physical Activity in People With Head and Neck Cancer(ProAct-HNC) | completed | — | 20 | Kantonsspital Winterthur KSWOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT04772989 | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies(ARC-12) | completed | Phase 1 | 94 | Arcus Biosciences, Inc.INDUSTRY | 3 | Aug 28, 2025 | clinicaltrials |
| NCT07143097 | Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer | completed | Phase 2 | 80 | Beni-Suef UniversityOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT07143955 | Dietary Intervention and Gut Microbiota in Hepatocellular Carcinoma (HCC) | completed | N/A | 100 | The First Hospital of Hebei Medical UniversityOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT01723202 | Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer | completed | Phase 2 | 53 | Bhavana KondaOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT05880082 | PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer(PPIO-004-EC001) | completed | Phase 2 | 118 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT03588091 | Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer | completed | Phase 3 | 355 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT04191421 | Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 35 | Emory UniversityOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT05752669 | Oxidative Stress and Mitochondrial TERT in Papillary Thyroid Cancer.(TEMPEST) | completed | — | 100 | Istituto Auxologico ItalianoOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT03708328 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 134 | Hoffmann-La RocheINDUSTRY | 6 | Aug 20, 2025 | clinicaltrials |
| NCT03748186 | Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | completed | Phase 1 | 136 | Sutro Biopharma, Inc.INDUSTRY | 2 | Aug 20, 2025 | clinicaltrials |
| NCT07132957 | A Study of AL8326 in Healthy Subjects | completed | Phase 1 | 6 | Advenchen Laboratories Nanjing Ltd.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT04080284 | Trial of Maintenance With Niraparib- Uterine Serous Carcinoma | completed | Phase 2 | 22 | Northwell HealthOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT03638141 | CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab | completed | Phase 2 | 21 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06620510 | Retrospective Study of Long-Term Survival of "Immuncell-LC" in Patients Undergoing Curative Resection for HCC in Korea | completed | — | 230 | GC Cell CorporationINDUSTRY | 1 | Aug 15, 2025 | clinicaltrials |
| NCT04791176 | Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC | completed | Phase 2 | 64 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07117786 | Computed Tomography Radiomics-Derived Nomogram for Predicting Early Renal Function Decline After Partial Nephrectomy in Renal Cell Carcinoma: A Multicenter Development/Validation Study | completed | — | 1,437 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 0 | Aug 12, 2025 | clinicaltrials |
| NCT04487236 | Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors | completed | Phase 1 | 61 | Suzhou Zanrong Pharma LimitedINDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT04620200 | Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery(MATISSE) | completed | Phase 2 | 50 | The Netherlands Cancer InstituteOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06273852 | A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors | completed | Early Phase 1 | 8 | Pure Biologics S.A.INDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07115095 | Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer | completed | N/A | 98 | Nanlin LiOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT02003209 | Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer | completed | Phase 3 | 315 | National Cancer Institute (NCI)NIH | 2 | Aug 8, 2025 | clinicaltrials |
| NCT03623646 | Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.(CITHARE) | completed | Phase 2 | 11 | Institut Claudius RegaudOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT03685448 | ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)(UNICAB) | completed | Phase 2 | 35 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT03967522 | Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases(CABRAMET) | completed | Phase 2 | 26 | Centre Leon BerardOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT05678218 | Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma(POELH-II) | completed | — | 245 | Erasmus Medical CenterOTHER | 2 | Aug 8, 2025 | clinicaltrials |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer(CheckMate649) | completed | Phase 3 | 2,031 | Bristol-Myers SquibbINDUSTRY | 29 | Aug 7, 2025 | clinicaltrials |
| NCT05585034 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors | completed | Phase 1 | 60 | Xencor, Inc.INDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT01879657 | 68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs) | completed | N/A | 169 | Radio Isotope Therapy of AmericaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT04634539 | Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer | completed | Phase 1 | 18 | Jun Gong, MDOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07107503 | 10 Years' Follow-up Results of Ultrasound-guided Radiofrequency Ablation Versus Surgery for Low-risk Papillary Thyroid Micro-carcinoma | completed | — | 757 | Yi MaoOTHER | 0 | Aug 6, 2025 | clinicaltrials |
| NCT02903914 | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | completed | Phase 1 | 260 | Incyte CorporationINDUSTRY | 4 | Aug 5, 2025 | clinicaltrials |
| NCT03599713 | A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) | completed | Phase 2 | 107 | Incyte CorporationINDUSTRY | 12 | Aug 5, 2025 | clinicaltrials |
| NCT04197960 | Microwave Ablation and Surgical Resection for Micropapillary Thyroid Carcinoma | completed | N/A | 973 | Chinese PLA General HospitalOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT02013154 | A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab(P102) | completed | Phase 1 | 151 | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT05480306 | Phase 2 Study of DKN-01 in Colorectal Cancer(DeFianCe) | completed | Phase 2 | 188 | Leap Therapeutics, Inc.INDUSTRY | 3 | Aug 3, 2025 | clinicaltrials |
| NCT04458597 | Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus. | completed | N/A | 23 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Aug 1, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 4, 2025source: clinicaltrials